Can you reliably “beat the market” when selling your chemicals or life sciences business?

CCD Partners • Feb 03, 2020

(Yes, and here’s how….)

There is a reasonably common view amongst business owners that one should wait to be approached by a ‘really keen strategic buyer’ before engaging in sale discussions. The reasoning being that if the buyer approaches first this gives the seller the upper hand in negotiations and means there is a good chance of a buyer being interested.

This, on its own, is wrong and, rather counter-intuitively, gives away the upper hand and can lead to sellers trapped into below-market deals or no deal at all after months of hard work.

I previously wrote an article on what to do if you are approached by a ‘really keen strategic buyer’which looked into how sellers can give themselves the best chance in such a scenario. The thrust of this article is that sellers in this situation are starting on the back foot and must work hard to catch up and be lucky enough to be dealing with a counterparty that is both highly motivated and unusually honourable.

Rather than relying on such a buyer-led approach, I typically recommend a seller-led approach. Using the methods I outline below I have enjoyed 100% success in securing above-market sales over my last 4 years and 7 deals (ever since I started employing these methods in their current form).


How to reliably beat the market when selling a lower-mid market (i.e. valued between $10m to $100m) privately-owned chemicals or life sciences business.

At the most basic level, securing a high price for a business requires a) the buyer to believe it is worth a high price, b) the buyer to believe they have to pay a high price, and c) nothing to go wrong before completion.

So, to achieve each of these, the core objectives of any seller-led sale process should be:

Objectives

  • Maximise the perceived value of the business to buyers "Value Perception"
  • Maximise the negotiation power of the sellers "Negotiation Power"
  • Maximise the certainty that the deal will complete "Deal Certainty"

Every business is unique, and every sale process should be tailored accordingly, but it is possible to talk in general about the following core workflows:

Workflows

  1. Narrative Development
  2. Preparation and Presentation
  3. Process Design

Taking each in turn…


1. Narrative Development

As I explore in my article “The most important thing to do when selling a chemicals or life sciences company” , developing a single compelling transaction narrative is critical to value. Such a narrative needs to inspire excitement in buyers, pull together all the strands of the deal in an understandable way, and build the platform for negotiations.

The narrative is the backbone of any process and is critical to get right.

Specific examples of what the narrative must do include:

  • Value Perception – ensure buyers are convinced of the strategic potential to them
  • Negotiation Power – ensure buyers believe there are credible alternatives to their offer
  • Deal Certainty – ensure the business appeals to a good number of buyers


2. Preparation and Presentation

Selling (and buying) a business is highly complex with hundreds of variables that each impact the final value. How the data is analysed, how it is presented, and how it is incorporated into any deal are all decisions that need to be made at various stages throughout the process. Furthermore, the sale of a company is not just about the business being sold – it is also about how that business might fit and interact with potential buyers’ businesses, which can often be in less-familiar markets.

As I discuss in my articles “When is analytical commercial due diligence not enough” and “How are privately-owned chemicals and life sciences companies valued” , a thorough grasp of accounting, transaction structuring, company valuation, and a techno-commercial understanding of multiple interacting dynamic markets is all simultaneously required to optimally prepare and present a chemical company for sale.

Specific examples of preparation and presentation required include:

  • Value Perception – ensure that sellers identify and present the full potential value of their business to all buyers (even those in less-familiar markets)
  • Negotiation Power – ensure all the key details are known and understood when headline deal terms are agreed
  • Deal Certainty – minimise the chance nasty surprises (internal or external) are revealed during due diligence


3. Process Design

A key aspect of a seller-led process is that the sellers can design and time the process to suit them. In a seller-led process it is much easier to design a timetable of work that focuses negotiation power during the short windows during which the key terms of a potential deal are agreed, that leaves sufficient time to prepare and execute with potential buyers, and that coincides with favourable seasonal conditions associated with the seller’s business (e.g. accounts preparation, typically strong sales months, and others).

Additionally, as I discuss further in my article “Selling your chemicals or life sciences business: why a slow process can erode value, and how to avoid it” , a slow process can kill a deal and so must be avoided through good process design.

Specific examples of what the process must do include:

  • Value Perception – ensure the business is perceived as a ‘prize asset’ being sold through a highly professional tailored process
  • Negotiation Power – ensure the factors that maximise negotiation power are focused to apply during the periods in which deal terms are agreed
  • Deal Certainty – minimise the time the business is “on the market” (when it is vulnerable to otherwise uncontrollable external factors)


In conclusion

It is possible to sell a lower-mid market privately-owned chemicals or life sciences business at above-market values.

However, to do it reliably , requires all of the following:

  1. a full range of transaction skills and techno-commercial insight into adjacent niche markets,
  2. a specialist and wide-reaching network of potential buyers and investors, but most of all
  3. a pro-active seller-led approach and highly dedicated work ethic that is focused on delivering the three core objectives of Value Perception, Negotiation Power, and Deal Certainty.

I have not seen it work any other way. Yes, it can help if a seller is approached before or during such a process and there are success stories from buyer-led deals, but these are comparatively rare and the failures (that are typically not made public) are far more numerous.

If you are interested in reading more on this topic I recommend “How much should you pay an M&A advisor to sell your chemicals or life sciences business?” , which sets out more on the different styles of approach to company sales and the associated success rates.

CCD Partners is a consultancy specialised in corporate transformations in small and mid-market chemicals and life sciences businesses.

To organise a call with one of our partners please email contact@ccdpartners.com

Receive M&A news relevant to your business

At critical moments our clients engage us to provide pre-publicity "off-market" intelligence to give them the edge over the competition - we also provide up-to-the-minute public or "on-market" intelligence for free

Contact Us

We're committed to your privacy. CCD Partners uses the information you provide to us to contact you about our relevant content, products, and services. You may unsubscribe at any time. For more information, please see our Privacy Policy.   

RECENT POSTS

By Matt Dixon 05 Dec, 2022
Market leading provider of formulated chemical process aids and foam control, PennWhite has been acquired by Manali Petrochemicals, part of the AM International Holdings group.
By Matt Dixon 02 Dec, 2022
Global source of industrial gas news, views, and debate, gas world has been sold by John and Karen Raquet to the senior management team in an MBO, backed by Mobeus Equity Partners.
By Matt Dixon 13 Sep, 2022
Polyblend UK Ltd is one of the market leaders in PVC based polymers. We are experts in manufacturing a comprehensive range of liquid plastisol and dispersion systems, complemented by our Speciality Distribution business supplying plasticisers, resins and PVC additives.
By Matt Dixon 05 May, 2022
GFBiochemicals is a sustainable chemicals company that produces levulinic acid derivatives at commercial scale directly from biomass. Having perfected its technology, product, and certification, the company is entering a new phase of commercialization.
By CCD Partners 20 Apr, 2022
In the latest episode of the Chemical Transformations podcast , CCD Partners' Managing Partner Matt Dixon speaks with Ted Clark, former President and CEO of Royal Adhesives & Sealants, discussing his new book "Shipping Clerk to CEO: The Power of Curiosity, Will, and Self Directed Learning”. The book tells the story of Clark’s remarkable career journey from entry-level worker to CEO of a $240m chemical company by the age of 42.
By Matt Dixon 04 Feb, 2022
Esteve Química purchases one of the UQUIFA Group's two pharmaceutical fine chemicals plants in Barcelona.
By Matt Dixon 04 Feb, 2022
Specialty materials manufacturer Vertellus has acquired Polyscope Polymers B.V., a global leader in specialty additives for coatings, electronics applications, and engineering polymers.
By Matt Dixon 01 Nov, 2021
Biosynth Carbosynth is a fully hybrid Research Products, Life Sciences Reagents and Custom Synthesis and Manufacturing Services Company with global research, manufacturing and distribution facilities. They are the supplier of choice for many in the pharmaceutical, life science, food, agrochemical, cosmetic and diagnostic sectors and manufacture and source a vast range of chemical and biochemical products.
By CCD Partners 12 Oct, 2021
Steve Allin co-founded Charnwood Molecular with Phil Page in 1998. 22 years later, the business has evolved dramatically from its origins as a spinout of Loughborough University. Backed by a partnership with Synova Capital, the company is now preparing to move into a former AstraZeneca research facility and has already completed its first M&A deal, acquiring Aurelia Bioscience in summer 2021. CCD Partners’ Matt Dixon spoke with Steve about the journey from full-time academia to running a high-growth market leader.
By Matt Dixon 24 Sep, 2021
Aspire was founded in 2009. Aspire has an asset-light business model that focuses on R&D, business development and sales and marketing, while outsourcing manufacturing and distribution to specialist third parties. For more details see www.aspirepharma.co.uk.
Show More
Share by: